Dynacure to Present Disease Progression Model and Natural History Study Data at the 25th Annual Congress of the World Muscle Society (WMS25) siteadmin2020-11-07T02:09:54-08:00September 28, 2020|
Dynacure Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for DYN101 for Myotubular and Centronuclear Myopathies (CNM) siteadmin2020-11-07T02:12:27-08:00July 30, 2020|
Dynacure Announces Presentations at Upcoming Investor Conferences siteadmin2020-11-07T02:13:48-08:00July 28, 2020|
Dynacure Announces Presentation at Jefferies Virtual Global Healthcare Conference siteadmin2020-11-07T02:15:15-08:00May 27, 2020|
Dynacure Announces First Patient Dosed in Phase 1 / 2 ‘UNITE-CNM’ Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM) siteadmin2020-11-07T02:19:18-08:00March 5, 2020|
Dynacure to Present at 40th Annual Cowen Healthcare Conference siteadmin2020-11-07T02:20:55-08:00February 26, 2020|
Dynacure’s Chief Scientific Officer, Dr. Belinda Cowling, Receives Irène Joliot-Curie Prize for Women in Business and Technology siteadmin2020-11-07T02:22:26-08:00November 27, 2019|
